Biocracked
Conceptual metaphor: a cube of pale yellow wax, the size of a fist, stands for abdominal fat. A clear glass syringe is inserted into its top face, and one small, smooth, glossy crater has melted around the needle. The rest of the cube stays sharp-edged and untouched, which shows the effect is local, not systemic. Fine droplets of melted wax bead at the crater's rim. The syringe plunger has a small electric green tip.

The camera is at a low three-quarter angle with a shallow depth of field, focused on the needle entry point. The cube sits on a seamless saturated teal backdrop and a matching glossy teal surface, with a faint reflection beneath it. Soft, directional studio light comes from the upper left, giving the wax a translucent glow and crisp highlights on the glass. Shadows are neutral grey-teal, not blue-black.

The mood is precise, curious and slightly skeptical, with a clean, modern, photorealistic look.
Research

What is CBL-514? Does it burn fat?

Dr. Synapse · · 5 min read

CBL-514 (sometimes mistyped as "CL-514") is being discussed online as a fat-dissolving shot. The description is partly right, but "fat burner" is the wrong frame. CBL-514 is an investigational small-molecule injection lipolysis drug from Caliway Biopharmaceuticals of New Taipei City, Taiwan. It is designed to trigger fat-cell death in the area where it is injected. It is not a metabolic fat burner, not a GLP-1, and not a supplement.

Here is what the published human data actually show.

What CBL-514 is, and what it is not

The correct name is CBL-514. "CL-514" is a typo that shows up in searches, and it is the only time it appears in this article.

CBL-514 is:

  • An investigational small-molecule injectable.
  • Given as subcutaneous injections into a treated area. In the Phase 2 trial, that area was abdominal fat.
  • Administered by investigators in a clinical trial.

CBL-514 is not:

  • A supplement or an oral pill.
  • An approved consumer product.
  • FDA-approved, as of the Phase 2 paper.

The only FDA-approved injectable for fat reduction mentioned in the paper is ATX-101 (deoxycholic acid, sold as Kybella). It is approved only for submental fat, the fat under the chin. CBL-514 is being studied for a much larger area, the abdomen, but it remains an experimental compound.

The proposed mechanism

The Phase 2 paper describes CBL-514 as "a small-molecule injection lipolysis agent that promotes adipocyte apoptosis and targeted subcutaneous fat reduction in nonclinical studies." Those nonclinical claims rest partly on unpublished, confidential Caliway reports and on the earlier, smaller, open-label Phase 2a paper (Goodman et al., 2022). According to that earlier work, CBL-514 inhibits the cell-survival kinase DYRK1b and upregulates the apoptosis mediators caspase 3 and Bax/Bcl-2. This is reported to produce dose-dependent adipocyte apoptosis in vitro and in vivo. In plain terms, the idea is to push fat cells in the injected zone toward programmed cell death, not to raise your metabolic rate or burn calories across the body. The chemical structure of the molecule has not been disclosed in these papers, so any claim about its exact identity, receptor, or ingredients is speculation.

The human evidence: a 2025 Phase 2 trial

The main human data come from a randomized, single-blind, placebo-controlled Phase 2 trial. It was run at five centers in the US and Australia between February 2022 and March 2023 and published in Aesthetic Surgery Journal in 2025 (level of evidence 2).

  • Size: 130 screened, 81 enrolled, 76 randomized (50 CBL-514, 26 placebo), 75 treated.
  • Participants: adults aged 18 to 64 with a BMI above 18.5 and below 35 kg/m². In the CBL-514 group, 94% were women.
  • Dosing: up to four treatments at 4-week intervals. Each treatment used 25 to 50 injections of 2.4 mL at 2 mg/cm², up to 600 mg per treatment. The placebo was normal saline.
  • Measurement: ultrasound fat thickness at four points, converted to volume across a 300 cm² treatment area.

Blinding is a limitation. Only participants were blinded. Investigators, site staff, and the sponsor stayed unblinded. Caliway was also involved in study design, data analysis and interpretation, writing the manuscript, and the decision to publish.

So, does it burn fat?

It reduced local fat volume compared with placebo. It did not cause systemic fat burning or weight loss.

On local fat, the study met its primary endpoint of at least 150 mL of fat-volume loss. In the intention-to-treat (ITT) analysis:

  • 4 weeks after the last treatment: 63.9% of CBL-514 participants (23/36) reached at least 150 mL, versus 17.4% of placebo (4/23), P < .001.
  • 8 weeks: 69.6% (16/23) versus 0.0% (0/16), P < .001.
  • Average loss: the least-squares mean difference versus placebo was −206.62 mL at 4 weeks and −216.28 mL at 8 weeks.
  • Largest single loss: more than 750 mL in one participant.

On body weight, the CBL-514 group's mean change was +0.45 kg at the 4-week follow-up and +0.02 kg at 8 weeks. The placebo group changed by −0.76 kg and −0.26 kg. The paper reports no significant changes in mean weight or BMI. It also says some participants who gained more than 1 kg still showed localized fat loss, though that data was not shown. This pattern is what you would expect from a local fat-cell-clearing approach. It is the opposite of a metabolic fat burner.

Caveats to read before getting excited

These numbers are encouraging for an early trial, but the paper has real limitations.

  • High dropout. Of 75 treated participants, 38 completed the study and 37 did not, a non-completion rate of 49.3%. Reasons included loss to follow-up, withdrawal, weight instability, schedule problems, and adverse events (4 participants).
  • Shrinking denominators. The ITT percentages above rest on 36 and then 23 CBL-514 participants because of missing follow-up.
  • Small per-protocol group. The PP population was only 30 people. Its larger effects (a mean of about −314.70 mL at 4 weeks in the CBL-514 group) come from the people who stayed the course and kept a stable weight, so they flatter the drug.
  • Exploratory design. The sample size was not based on a formal power calculation, and the analysis did not adjust for multiple testing.
  • Narrow population. Participants were mostly women and mostly white.
  • Ultrasound-derived volumes. Volume was calculated with a cuboid formula from ultrasound thickness, not measured directly.

The authors also compare the results with cryolipolysis studies and say the trend "appears to be larger," and they describe results as comparable to liposuction. These are the authors' interpretations. Measurement methods differed, and there was no head-to-head trial against CoolSculpting or liposuction. The authors' impression of little or no skin laxity comes from posttreatment images, not a formal laxity endpoint.

Safety was assessed through adverse events, labs, vitals, ECGs, physical exams, and injection-site reactions. Readers who care about tolerability should go through the safety section of the full paper rather than rely on a summary.

The bottom line for biohackers

CBL-514 is an interesting piece of biotech: a small molecule meant to make fat cells in a treated area undergo apoptosis. The Phase 2 data suggest it can reduce abdominal fat volume more than saline, with essentially no change in body weight. That is the signature of a targeted body-contouring drug, not a fat burner.

It is also investigational. It is not approved, and it is not a supplement. It is not something to source or self-inject. Anything sold online under this name outside a clinical trial is an unknown, and the compound's structure has not even been disclosed. Larger, better-blinded, longer-term trials will have to show whether the early results hold up.

Source: Gold M, Schlessinger J, Goodman GJ, et al. Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study. Aesthet Surg J. 2025;45(6):611-620. PMC12080885 | PMID 40037659 | doi.org/10.1093/asj/sjaf032

More from this CBL-514 series

This article is part of our CBL-514 series. For the full Phase 2 trial overview, start here: CBL-514 Injection Lipolysis: A Phase 2 Map of the Evidence.

Original study

Read the original research on pmc.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach 1, macro science, with Palette D, bold color field.

Extreme close-up microscopy-style photograph of a cluster of adipocytes (fat cells). Each is a translucent, pale yellow sphere with a thin membrane, and a few are shrunken and crinkled to suggest apoptosis. The cells sit against a saturated magenta backdrop. The camera is slightly above, at a shallow 30-degree angle, with a very shallow depth of field so the foreground cells are razor sharp and the rest melts into soft bokeh. Hard, clean side light from the left makes the membranes glisten and casts crisp magenta-tinted shadows. One tiny electric green fluorescent speck glows inside a single collapsing cell as a subtle accent. The mood is precise, clinical and curious, with a bold editorial feel. There is no text and no blue cast.
research

CBL-514 Injection Lipolysis: A Phase 2 Map of the Evidence

BY DR. SYNAPSE ·

CBL-514 is an investigational injection that aims to trigger fat-cell apoptosis in a treated abdominal area. In a 2025 Phase 2 trial of 76 randomized participants, it produced large ultrasound-measured fat-volume losses versus saline while mean body weight stayed flat. This hub maps the design, the 2 mg/cm² dosing, the exact efficacy figures with their shrinking denominators, and the company-reported DYRK1b/caspase mechanism. It also spells out the caveats: single-blind design, sponsor involvement, about 49% non-completion, short follow-up and a mostly female sample. Five deeper explainers are linked for readers who want to go further.

Approach 2, lab in action, with palette D, bold color field.

Straight-on, slightly elevated close shot of a gloved hand in a pale nitrile glove holding a glass syringe with a fine needle. The syringe is filled with clear liquid and sits over a row of small glass vials in a matte white rack. The whole scene sits against a saturated tomato-red seamless backdrop. Soft, even studio light gives crisp highlights along the syringe barrel and the vial glass, plus gentle warm-red reflections on the surfaces. A thin electric green (#00e676) cap on one vial is the only small accent. The dosing markings on the syringe are blurred and unreadable. Shallow depth of field blurs the back vials into soft shapes. The mood is precise, clinical and investigational, with high contrast and a measured, careful feel. No text, no labels, no logos.
research

CBL-514 Dosages - what does science say?

BY DR. SYNAPSE ·

CBL-514 trials are investigational injection protocols, and the "600 mg" figure is a per-treatment cap, not a supplement dose. This article walks through the Phase 2a dose-finding study (1.2, 1.6 and 2.0 mg/cm² over 150 cm², n=43, open-label) and explains where the much-quoted 24.96% figure comes from. It then covers the placebo-controlled Phase 2, which kept 2.0 mg/cm² but doubled the area to 300 cm² and raised the cap to 600 mg. You will see why mg totals cannot be compared across studies, what safety was reported, and why this is still not approved or advice.

Approach: the human outcome. Palette: bold color field.

A close, slightly high three-quarter view of a bare abdomen, cropped at the ribs and hips with no face. A hand in an electric green (#00e676) nitrile glove pinches a fold of belly skin and holds a slim syringe with the needle just about to enter. Faint yellow-purple bruising near the injection site hints at the side effects. The torso fills the frame against a flat, saturated teal backdrop that contrasts with the warm skin tones. Soft, even studio light from the left gives gentle shadows and visible skin texture, with fine pores and small hairs. The syringe tip is in sharp focus and the background falls away. No text or markings anywhere. The mood is clinical, unsentimental and skeptical.
research

Does CBL-514 really burn fat? Here's what we know

BY HELIX WARD ·

The 2025 Phase 2 CBL-514 trial did not test weight loss. It tested whether an abdominal injection could cut at least 150 mL of subcutaneous fat volume on ultrasound, and 69.6% (16/23) of treated participants got there at 8 weeks versus 0/16 on placebo. But mean body weight did not fall (+0.02 kg), nearly half of treated participants did not complete the study, and the per-protocol group was just 30 people. Injection-site reactions were common, including discoloration in 71.4% and severe pain in 18.4%. Here is the data-first breakdown of what the trial shows and what it doesn't.

**Approach 1 (macro science), Palette D (bold color field).**

Extreme close-up microscopy-style photograph of a cluster of fat cells (adipocytes), rendered as translucent, pearly spheres with thin membranes and tiny lipid droplets inside. One cell in the center is visibly shrinking and blebbing, its membrane crinkled and fragmenting into small beads, the look of apoptosis. A few of the surrounding cells are intact and glossy. The cells sit against a saturated tomato-red backdrop, so the pale yellow-cream spheres stand out sharply. The camera looks straight down at shallow depth of field, with the focal plane on the dying cell and the edges softly blurred. Soft, diffuse top light gives gentle highlights and warm shadows, with no blue cast. One thin electric green fluorescent ring around the central cell's nucleus is the only green accent. The mood is analytical, precise and quietly skeptical.
research

How does CBL-514 work? Here's the science

BY DR. SYNAPSE ·

CBL-514 is not framed as a fat-melting or fat-burning drug. The proposed claim is that it inhibits the survival kinase DYRK1b and pushes fat cells toward apoptosis through caspase 3 and Bax/Bcl-2. That evidence comes from unpublished company reports cited in the Phase 2a and Phase 2 papers, and the chemical structure has not been disclosed. The 2025 Phase 2 trial measured ultrasound fat volume, photos, and safety, with no human biopsy or caspase data. This article separates the molecular hypothesis from what was actually measured in people, including the high dropout and single-blind design.

This page is available in